Solid phase chemistry approach to the SAR development of a novel class of active site-directed thrombin inhibitors

Tetrahedron

Volumn 55, Issue 39, 1999, Pages 11641-11652

  Johnson, Mary George ^a   Bronson, Duane D ^a   Gillespie, Jan E ^a   Gifford Moore, Donetta S ^b   Kalter, Kyomi ^a   Lynch, Michael P ^a   McCowan, Jefferson R ^b   Redick, Catherine C ^a   Sall, Daniel J ^b   Smith, Gerald F ^b   Foglesong, Robert J ^a  

^a Sphinx Pharmaceuticals Corporation   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOTHIOPHENE DERIVATIVE; THROMBIN INHIBITOR;

ARTICLE; CATALYSIS; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; REACTION ANALYSIS;

EID: 0033600889     PISSN: 00404020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4020(99)00684-5     Document Type: Article

References (25)

1. For a general discussion of the role of thrombin in thrombus formation, see: (a) Machovich, R. Thrombin and hemostasis. In The Thrombin; Machovich, R.; CRC Press, Inc.: Boca Raton, Fl. 1984; Vol 1, ppl-22.
2. (b) Hirsh, J.; Salzman, E.W.; Marder, V. J.; Colman, R.W. Overview of the thrombotic process and its therapy. In Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 2nd Ed.; Colman, R.W.; Hirsh, J.; Marder, V.J.; Salzman, E.W., Eds.; J.B. Lippincott Co.: Philadelphia, PA, 1987; pp 1063-1072.
3. (c) Hirsh, J.; Salzman, E.W. Pathogenesis of venous thromboembolism. In Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 2nd Ed.; Colman, R.W.; Hirsh, J.; Marder, V.J.; Salzman, E.W., Eds.; J.B. Lippincott Co.: Philadelphia, PA, 1987; pp 1199-1207.
4. (d) Barnett, H.J.M. Thrombotic processes in cerebrovascular disease. Ibid.; pp 1301-1315.
5. (a) Colman, R.W.; Marder, V. J.; Salzman, E.W.; Hirsh, J. Overview of hemostasis. In Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 3rd Ed.; Colman, R.W.; Hirsh, J.; Marder, V.J.; Salzman, E.W., Eds.; J.B. Lippincott Co.: Philadelphia, PA, 1994; pp 3- 18.
6. (b) Mann, K.G. Prothrombin and thrombin. Ibid.; pp 184-199.
7. (c) Colman, R.W.; Cook, J.J.; Niewiarowski, S. Mechanisms of platelet aggregation. Ibid.; pp 508-523.
8. (d) Edit, J.F.; Allison, P.; Noble, S.; Ashton, J.; Golino, P.; McNard, JH.; Buja, L.M.; Willerson, J.T. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J. Clin. Invest. 1989, 84, 18.
9. (e) Heras, M.; Chesbro, J.H.; Penny, W.J.; Bailey, K.R.; Badimon, L.; Fuster, V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposit or during angioplasty in pigs. Heparin vs hirudin, a specific thrombin inhibitor. Circulation 1989, 79, 657-665.
10. For recent reviews on approaches to the design of active-site directed thrombin inhibitors see a) Edmunds JJ, Rapundalo ST, Ann. Rep. Med. Chem. 1996, 31, 51-60.
11. b) Scarborough R M. Ann. Rep. Med. Chem. 1995, 30, 71-80.
12. c) Wiley MR, Fisher MJ, Exp. Opin. Ther. Patents 1997, 7, 1265-1282.
13. d) See also: Lumma, W. C.; Witherup, K. M.; Tucker, T. J.; Brady, S. F.; Sisko, J. T.; Naylor-Olsen, A. M.; Lewis, S. D.; Lucas, B. J.; Vacca, J. P. J. Med. Chem. 1998, 41, 1011-1013
14. Brady, S. F.; Stauffer, K. J.; Lumma, W. C.; Smith, G. M; Ramjit, H. G.; Lewis, S. D.; Lucas, B. J.; Gardell, S. J.; Lyle, E. A.; Appleby, S. D.; Cook, J. J.; Holahan, M. A.; Stranier, M. T.; Lynch, J. J.; Lin, J. H.; Chen, I-W.; Vastag, K.; Naylor-Olsen, A. M.; Vacca, J. P. J. Med. Chem. 1998, 41, 401-406, for a discussion on solid-phase approaches to another class of active-site directed thrombin inhibitors. Non-basic inhibitors were also discovered in this work.
15. Sall, D.J.; Bastian, J.A. ; Briggs, S.L.; Buben, J.A.; Chirgadze, N.Y.; Clawson, D.K.; Denney, M.L.; Gierra, D.D.; Gifford-Moore, D.S.; Harper, R.W.; Hauser, K.L.; Klimkowski, V.J.; Kohn, T.J.; Lin, H-S.; McCowan, J.R.; Palkowitz, A.D.; Smith, G.F.; Takeuchi, K.; Thrasher, K.J.; Tinsley, J.M.; Utterback, B.G.; Yan, S-C.B.; Zhang, M. J. Med. Chem. 1997, 40, 3489-3493.
16. 6.
17. For a recent review see: Hughes, D. L. Organic Preparations and Procedures Int. 1996, 28, 127-164.
18. See also: a) Tsunoda, T.; Yamamiya, Y.; Ito, S. Tetrahedron Lett. 1993, 34, 1639.
19. b) Tsunoda, T.; Otsuka, J.; Yamamiya, Y.; Ito, S. Chem Lett. 1994, 539.
20. c) Tsunoda, T.; Yamamiya, Y.; Kawamura, Y.; Ito, S. Tetrahedron Lett. 1995, 36, 2529.
21. d) Tsunoda, T.; Ozaki, F.; Ito, S. Ibid 1994, 35, 5081.
22. e) Tsunoda, T.; Nagaku, M.; Nagino, C.; Kawamura, Y.; Ozaki, F.; Hioki, H.; Ito, S.Ibid 1995, 36, 2531.
23. Castro, J. L.; Matassa, V. G.; Ball, R. G. J. Org. Chem. 1994, 59, 2289-91.
24. ass) which were derived from inhibition kinetics as described, briefly, in the experimental section and as previously described in: Smith, G.F.; Gifford-Moore, D.; Craft, T.J.; Chirgadze, N.; Ruterbories, K.J.; Lindstrom, T.D.; Satterwhite, J.H. Efegatran: A new cardiovascular anticoagulant. In New Anticoagulants for The Cardiovascular Patient; Pifarre, R., Ed.; Hanley & Belfus, Inc.: Philadelphia, PA, 1997; pp 265-300.
25. Prepared according to the method of Frechet: Farall, M. J.; Frechet, J. M. J. J. Org. Chem. 1976, 41, 3877.